Anonymous
Guest
Anonymous
Guest
Barclays lowered its price target on shares of Merck from $43 to $41 Monday as the company doesn't have many revenue drivers coming to market this year or next.
Is this really true? Whom can I trust. The only value score that really matters is the one Wall Street assigns MRK every trading day. These other subjective metrics are meaningless.
Is this really true? Whom can I trust. The only value score that really matters is the one Wall Street assigns MRK every trading day. These other subjective metrics are meaningless.